{"id":"W4391180278","doi":"10.1016/j.jtho.2024.01.012","title":"Consolidation Osimertinib Versus Durvalumab Versus Observation After Concurrent Chemoradiation in Unresectable EGFR-Mutant NSCLC: A Multicenter Retrospective Cohort Study","year":2024,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":39,"is_retracted":false,"has_abstract":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"National Institute on Aging; University of California, Irvine; EMD Serono; Genentech; European Society for Medical Oncology; G1 Therapeutics; Seagen; Relay Therapeutics; University of California, San Francisco; NGM Biopharmaceuticals; Cancer Research Institute; AstraZeneca; Novocure; ViewRay; Celldex Therapeutics; Ipsen; Jazz Pharmaceuticals; National Institutes of Health; Regeneron Pharmaceuticals; International Association for the Study of Lung Cancer; Mirati Therapeutics; Association of American Medical Colleges; GlaxoSmithKline; Pfizer; American Association for Cancer Research; Amgen; American Society of Clinical Oncology; Eli Lilly and Company; Bristol-Myers Squibb; Hope Foundation; Sociedad Española de Oncología Médica; Society for Immunotherapy of Cancer; LUNGevity Foundation; Daiichi Sankyo Europe; National Cancer Institute; Gilead Sciences; Conquer Cancer Foundation; Sanofi","keywords":"Durvalumab; Medicine; Osimertinib; Common Terminology Criteria for Adverse Events; Retrospective cohort study; Clinical endpoint; Internal medicine; Oncology; Proportional hazards model; Hazard ratio; Cohort; Adverse effect; Confidence interval; Adenocarcinoma; Cancer; Randomized controlled trial; Nivolumab","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007103253,0.0001662849,0.0005081808,0.0003419875,0.00004794634,0.00004920541,0.00006735997,0.0001200148,0.0002298228],"category_scores_gemma":[0.000357141,0.0001352965,0.0001209251,0.0004321408,0.00004686112,0.0003709689,0.00002472801,0.0004118369,0.00002869629],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.003753525,"about_ca_system_score_gemma":0.0008396634,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0000891222,"about_ca_topic_score_gemma":0.0002192891,"domain_scores_codex":[0.998206,0.0002007347,0.0006912689,0.0002633377,0.0004146882,0.0002239787],"domain_scores_gemma":[0.9987245,0.0002642845,0.0003275653,0.0001491499,0.0004230742,0.0001114216],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.05012574,0.004309178,0.8330128,0.0002106481,0.003185932,0.002174519,0.009140204,0.0002093435,0.001983069,0.0001057504,0.001025736,0.0945171],"study_design_scores_gemma":[0.01759853,0.008300828,0.9598243,0.0003779531,0.002768449,0.00008570696,0.002243822,0.003165408,0.0008895281,0.00003058633,0.004536716,0.0001782069],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.990373,0.0009455103,0.0001456204,0.001578423,0.004685189,0.00110343,0.00001629229,0.00002511653,0.001127411],"genre_scores_gemma":[0.9987583,0.0001073228,0.0003475694,0.00007185907,0.0003949346,0.0001087852,0.00003656073,0.00002284884,0.0001518846],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1268115,"threshold_uncertainty_score":0.9815336,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03540123169618212,"score_gpt":0.4502022867821959,"score_spread":0.4148010550860137,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}